Zajaczkowski W, Moryl E, Papp M
Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland.
Pharmacol Biochem Behav. 1996 Sep;55(1):163-8. doi: 10.1016/0091-3057(95)02290-2.
Rats were trained to discriminate MK-801 (0.05 mg/kg, IP), an uncompetitive, or CGP 37849 (3 mg/kg, IP), a competitive NMDA receptor antagonist from saline, using a two-lever, operant drug discrimination paradigm. In generalization tests the role of dopaminergic and serotonergic systems in the discriminative stimulus effects produced by both NMDA receptor antagonists was studied with amphetamine (0.5 mg/kg), cocaine (5.0 and 7.5 mg/kg), and fenfluramine (2.5 and 5.0 mg/kg). Additionally, memantine (5.0, 7.5 and 10.0 mg/kg), an uncompetitive NMDA receptor antagonist, was tested. The discriminative stimuli produced by MK-801 and CGP 37849 were not generalized to each other. Among the tested drugs only memantine generalized to the MK-801 discriminative stimulus. None of the tested drugs showed CGP 37849-like discriminative stimulus properties. The different mechanisms underlying NMDA antagonism by MK-801 and GP 37849 might explain the observed lack of cross-generalization. The results suggest that dopaminergic and serotonergic systems are not of major importance in the discriminative stimulus effects produced by both MK-801 and CGP 37849.
采用双杠杆操作性药物辨别范式,训练大鼠区分非竞争性NMDA受体拮抗剂MK-801(0.05mg/kg,腹腔注射)或竞争性NMDA受体拮抗剂CGP 37849(3mg/kg,腹腔注射)与生理盐水。在泛化试验中,使用苯丙胺(0.5mg/kg)、可卡因(5.0和7.5mg/kg)以及芬氟拉明(2.5和5.0mg/kg)研究多巴胺能和5-羟色胺能系统在两种NMDA受体拮抗剂产生的辨别性刺激效应中的作用。此外,还测试了非竞争性NMDA受体拮抗剂美金刚(5.0、7.5和10.0mg/kg)。MK-801和CGP 37849产生的辨别性刺激彼此不泛化。在所测试的药物中,只有美金刚能泛化为MK-801的辨别性刺激。没有一种测试药物表现出类似CGP 37849的辨别性刺激特性。MK-801和GP 37849对NMDA拮抗作用的不同机制可能解释了所观察到的缺乏交叉泛化的现象。结果表明,多巴胺能和5-羟色胺能系统在MK-801和CGP 37849产生的辨别性刺激效应中并非起主要作用。